# BioNTech (BNTX) Stock Price, News & Analysis
Canonical URL: https://biopharmsignal.com/company/BNTX
## Company Profile
- Ticker: BNTX
- Exchange: NASDAQ
- Sector: Nucleic Acid Drugs
- Location: Mainz, Germany
- Tags: Immunotherapy, Tumor mRNA Vaccines, Nucleic Acid Drugs, Oncology, Immunology
## Stock Data
- Close: 92.8 USD
- Market cap: 22542103025.54 USD
- Last updated: 2026-08-11
## Business Overview
### Next-Generation Biopharmaceutical Platform
BioNTech develops medicines for cancer and other serious diseases using complementary immunotherapy and vaccine technologies. Its current oncology strategy integrates checkpoint and angiogenesis modulation, antibody-drug conjugates and mRNA cancer immunotherapies across multiple tumor types.
### Pumitamig
Pumitamig, also known as BNT327 or BMS986545, is a bispecific immunomodulator that combines PD-L1 checkpoint inhibition with VEGF-A neutralization. BioNTech and Bristol Myers Squibb are evaluating it in a broad pivotal program spanning lung, breast, colorectal, gastric and other solid tumors.
### Gotistobart
Gotistobart is a tumor-microenvironment-selective CTLA-4 antibody designed to deplete regulatory T cells. The Phase 3 PRESERVE-003 trial is evaluating it in metastatic squamous non-small cell lung cancer after platinum chemotherapy and PD-(L)1 treatment.
### HER2-Targeted ADC
Trastuzumab pamirtecan is a HER2-targeted antibody-drug conjugate partnered with DualityBio. It is being developed in recurrent endometrial cancer and HER2-low metastatic breast cancer through potentially registrational cohorts and Phase 3 trials.
### B7H3-Targeted ADC
BNT324, or DB-1311, is a B7H3-targeted antibody-drug conjugate with clinical activity under evaluation in prostate, cervical and ovarian cancers. A Phase 3 trial against docetaxel in metastatic castration-resistant prostate cancer is planned.
### Infectious-Disease Vaccines
BioNTech’s commercial vaccine business remains anchored by its COVID-19 collaboration with Pfizer. The partners continue to adapt the vaccine to circulating variants and prepare for seasonal regulatory approvals and supply.
## Why The Stock Is Moving

As of Aug 11, 2026, BNTX was little changed and closed at $92.80. No new same-company headline was identified in the current news window.

## Future Catalysts

- Phase 2 data from the ROSETTA Lung-02 pumitamig trial at ASCO on May 29–June 2, 2026.
- Multiple pumitamig combination readouts expected during 2026.
- Interim pivotal-stage data from the Phase 3 PRESERVE-003 gotistobart trial expected in 2026.
- BLA submission for trastuzumab pamirtecan in endometrial cancer planned in 2026, subject to regulatory feedback.
- Phase 3 DYNASTY-Breast02 data for trastuzumab pamirtecan expected in 2026.
- Initiation of the Phase 3 BNT324 trial in metastatic castration-resistant prostate cancer expected in 2026.
- Potential launch of a variant-adapted COVID-19 vaccine ahead of the 2026/2027 vaccination season, pending approval.

## Recent News
- 2026-08-04 10:45 EST — [BioNTech veröffentlicht Ergebnisse für das zweite Quartal 2026 sowie Informationen zur Geschäftsentwicklung](https://biopharmsignal.com/news/BNTX/biontech-ver-ffentlicht-ergebnisse-f-r-das-zweite-quartal-2026-sowie-information-2f0be20d) — Source: BioNTech
- 2026-08-04 10:45 EST — [BioNTech Announces Second Quarter 2026 Financial Results and Corporate Update](https://biopharmsignal.com/news/BNTX/biontech-announces-second-quarter-2026-financial-results-and-corporate-update-20d0ffe1) — Source: BioNTech
- 2026-08-03 09:00 EST — [BioNTech ernennt Dr. Guido Oelkers zum neuen Vorstandsvorsitzenden](https://biopharmsignal.com/news/BNTX/biontech-ernennt-dr-guido-oelkers-zum-neuen-vorstandsvorsitzenden-ee848391) — Source: BioNTech
- 2026-08-03 09:00 EST — [BioNTech Announces Appointment of Guido Oelkers to Management Board as Chief Executive Officer](https://biopharmsignal.com/news/BNTX/biontech-announces-appointment-of-guido-oelkers-to-management-board-as-chief-exe-ec8ad74b) — Source: BioNTech
- 2026-07-29 20:30 EST — [Europäische Kommission genehmigt Marktzulassung des an XFG angepassten COVID-19-Impfstoffs von Pfizer und BioNTech  in der Europäischen Union](https://biopharmsignal.com/news/BNTX/europ-ische-kommission-genehmigt-marktzulassung-des-an-xfg-angepassten-covid-19--ca9e72a1) — Source: BioNTech